CA2928071C — Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Assigned to Wyeth LLC · Expires 2017-04-25 · 9y expired
What this patent protects
The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro -4-(2-hyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino) -2-butenamide, (NERATINIB) methods of preparing crystalline maleate salt forms, the associated compounds, such as its degrad…
USPTO Abstract
The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro -4-(2-hyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino) -2-butenamide, (NERATINIB) methods of preparing crystalline maleate salt forms, the associated compounds, such as its degradation and impurities and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.